TABLE 2.

Summary of miRNAs involved in drug resistance in targeted therapy of NSCLC.

dslrMiRNAs	Drugs	Target	Mechanisms	References
miR-135a	gefitinib	PI3K/Akt	promoted cell growth and metastasis and activated the PI3K/AKT signaling pathway	Zhang and Wang. (2018)
miR-522-3p	gefitinib	PI3K/AKT	activating PI3K/AKT signaling pathway	Liu et al. (2020)
miR-200c-3p	gefitinib	c-Met	promotes EMT and inhibit apoptosis	Wang et al. (2020)
miR-103	gefitinib	Bcl-2	inhibit apoptosis and promote epithelial-mesenchymal transformation	Garofalo et al. (2011)
miR-203	gefitinib	Bcl-2
miR-19a	gefitinib	c-Met	through targeting c-Met 3′UTR regulation and c-Met protein dependence	Cao et al. (2017)
miR-506-3p	gefitinib	EMT	inhibiting EMT	Haque et al. (2020)
miR-630	gefitinib	miR-630/YAP1/ERK feedback loop	persistent activation of ERK signaling via the miR-630/YAP1/ERK feedback loop	Wu et al. (2018)
miR-135	gefitinib	TRIM16	by targeting TRIM16 as a tumor promoter, it is involved in the inherent mitochondrial apoptosis, caspase and JAK/STAT pathways in NSCLC cells	Wang and Zhang. (2018)
miR-223	erlotinib	FBXW7	activation of Akt and Notch signaling pathways	Zhang et al. (2017)
miR-873	gefitinib	GLI1	induced cell proliferation	Jin et al. (2018)
mir-6253p	gefitinib	AXL	via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer	Du et al. (2020)
miR-196a	gefitinib	GLTP	inducing cell proliferation and inhibiting cell apoptosis	Liu et al. (2022)
miR-326	gefitinib	IFNAR2	prostate cancer-associated transcription 6 (PCAT6) activates the miR-326/IFNAR2 axis	Zheng et al. (2022)
miR-323-3p	oximitinib	PI3K/Ak	PI3K-Akt signaling pathway	Janpipatkul et al. (2021)
miR-1468-3p
miR-5189-5p
miR-6513-5p
let-7c	osimertinib	WNT1, TCF-4	reduced proliferation and invasion	Li et al. (2020)
miR-210	osimertinib	E-cadherin	promote vimentin expression	Hisakane et al. (2021)
miR-184/miR-3913-5p	osimertinib	RAS-MAPK/PI3K	ctivation or abnormal regulation by bypass pathways	Li et al. (2021b)